37466-89-0

Basic information

• Product Name: 3-METHOXY-BENZENE-1,2-DIAMINE
• Synonyms: 3-METHOXY-BENZENE-1,2-DIAMINE;2,3-Diaminoanisole;1,2-Diamino-3-methoxybenzene;3-Methoxy-1,2-phenylenediamine;1,2-BenzenediaMine, 3-Methoxy-;Methoxy-para-phenylenediaMine;2,3-DiaMinoanisol;3-Methoxy-o-phenylenediaMine, 97%
• CAS NO: 37466-89-0
• Molecular Formula: C₇H₁₀N₂O
• Molecular Weight: 138.17
• Mol File: 37466-89-0.mol
• Article Data: 29

Chemical Properties

• Melting Point: 77-78℃
• Boiling Point: 286.3 °C at 760 mmHg
• Flash Point: 148.5 °C
• Appearance: /
• Density: 1.17 g/cm3
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.10±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-METHOXY-BENZENE-1,2-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXY-BENZENE-1,2-DIAMINE(37466-89-0)
• EPA Substance Registry System: 3-METHOXY-BENZENE-1,2-DIAMINE(37466-89-0)

Safety Data

• HazardClass: 6.1
• Hazardous Substances Data: 37466-89-0(Hazardous Substances Data)

Usage

Uses

3-Methoxy-o-phenylenediamine is used as pharmaceutical intermediate.

Upstream product

• 16315-07-4 2,3-dinitroanisole 
• 90-04-0 2-methoxy-phenylamine 
• 16554-47-5 3-methoxy-2-nitroaniline 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 158461-29-1 tert-butyl N-(2-nitro-3-methoxyphenyl)carbamate 
• 555-03-3 3-nitroanisole 
• 878769-98-3 1,2-diamino-3-methoxybenzene dihydrochloride 
• 603-85-0 2-Amino-3-nitrophenol 
• 7647-01-0 hydrogenchloride 
• 16554-45-3 2-methoxy-6-nitroaniline 

Downstream Products

• 578-50-7 2-heptafluoropropyl-4-methoxy-1(3)H-benzimidazole 
• 27080-53-1 4-methoxy-1H-benzo[d]imidazole 
• 19506-17-3 5-methoxyquinoxaline 
• 110534-24-2 4-methoxy-2-propyl-1H-benzo[d]imidazole 
• 76052-76-1 2-chloro-5-methoxy-quinoxaline 
• 405173-83-3 2-(chloromethyl)-4-methoxy-1H-benzimidazole 
• 1221265-68-4 3-(4-chlorophenyl)-5-methoxy-2-methylquinoxaline 
• 1221265-67-3 2-(4-chlorophenyl)-5-methoxy-3-methylquinoxaline 
• 76052-79-4 5-methoxy-1H-quinoxalin-2-one 
• 114224-42-9 2-ethyl-4-methoxy-1⁽³⁾H-benzoimidazole 
• 27077-75-4 4-methoxy-2-methyl-1H-benzo[d]imidazole 
• 18836-13-0 4-methoxy-2-phenyl-1H-benzo[d]imidazole 
• 111383-40-5 2-benzyl-4-methoxy-1⁽³⁾H-benzimidazole 
• 659729-61-0 8-methoxy-1H-quinoxalin-2-one 

Relevant articles and documents

Ni@Pd core-shell nanoparticles immobilized on yolk-shell Fe 3O4@polyaniline composites as a highly efficient, magnetically separable and atom-economical catalyst for reduction of nitrobenzenes

The preparation of Ni@Pd core-shell nanoparticles immobilized on yolk-shell Fe3O4@polyaniline composites is reported. Fe 3O4 nanoclusters were first synthesized through the solvothermal method and then the SiOs

Design, Synthesis, Biological Evaluation, and Molecular Modeling of 2-Difluoromethylbenzimidazole Derivatives as Potential PI3Kα Inhibitors

PI3Kα is one of the potential targets for novel anticancer drugs. In this study, a series of 2-difluoromethylbenzimidazole derivatives were studied based on the combination of molecular modeling techniques 3D-QSAR, molecular docking, and molecular dynamic

Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators

Recent studies examined the possibility to overcome imatinib resistance in chronic myeloid leukemia (CML) patients by combination therapy with peroxisome proliferator-activated receptor gamma (PPARγ) ligands. Pioglitazone, a full PPARγ agonist, improved the survival of patients by the gradual elimination of the residual CML stem cell pool. To evaluate the importance of the pharmacological profile of PPARγ agonists on the ability to circumvent resistance, the partial PPARγ agonist 4‘-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1’-biphenyl]-2-carboxylic acid, derived from telmisartan, and other related derivatives were investigated. The 4-substituted benzimidazole derivatives bearing a [1,1′-biphenyl]-2-carboxamide moiety sensitized K562-resistant cells to imatinib treatment. Especially the derivatives 18a-f, which did not activate PPARγ to more than 40% at 10 μM, retrieved the cytotoxicity of imatinib in these cells. The cell death modulating properties were higher than that of pioglitazone. It is of interest to note that all novel compounds were not cytotoxic neither on non-resistant nor on resistant cells. They exerted antitumor potency only in combination with imatinib.